Lipoprotein(a): more interesting than ever after 50 years
The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Abstract
PURPOSE OF REVIEW: Lipoprotein(a) [Lp(a)] is a risk factor for cardiovascular disease; we highlight the most recent research initiatives that have sought to define Lp(a)-dependent pathogenicity as well as pharmacologic approaches to lowering Lp(a). RECENT FINDINGS: Recent large-scale meta-analyses have confirmed elevated Lp(a) concentrations to be a moderate but consistent prospective coronary heart disease (CHD) risk factor. The Mendelian randomization approach has also associated LPA variants with Lp(a) concentration and CHD risk. Discoveries linking Lp(a) to oxidized phospholipid burden have implicated a proinflammatory role for Lp(a) hinting at a new mechanism underlying the association with CHD risk, which adds to previous atherogenic and thrombogenic mechanisms. Most existing Lp(a)-lowering drug treatments almost always show simultaneous effects on other lipoproteins, making it difficult to assign any clinical outcome specifically to the effects of Lp(a) lowering. Early experiments with antisense oligonucleotides targeting apolipoprotein(a) mRNA seem to indicate the pleiotropic effects of Lp(a) reduction on LDL and HDL in mice. The mechanism linking Lp(a) concentration with concentrations of other blood lipids remains unknown but may provide an insight into Lp(a) metabolism. SUMMARY: Despite the wealth of epidemiologic evidence supporting Lp(a) concentration as a CHD risk factor, the lack of a definitive functional mechanism involving an Lp(a)-dependent pathway in CHD pathogenesis has limited the potential clinical connotation of Lp(a). However, the application of novel technologies to the long-standing mysteries of Lp(a) biology seems to provide the opportunity for expanding our understanding of Lp(a) and its complex role in cardiovascular health.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“a LDL-like particle in which the apoB protein is linked by a disulfide bridge to apo(a)47.”
From Calcific aortic stenosis (2016) · cites this paper as [47]
In the citing paper
“[Statement]Hyper-Lp(a)-lipoproteinemia is a risk factor for ASCVD. (Evidence level: E-1a)”
From Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017 (2018) · cites this paper as [222]
In the citing paper
“When the size of apolipoprotein (a) [apo(a)] is small, the concentration of Lp(a) is high, and there is a high risk of CVD.”
From Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017 (2018) · cites this paper as [222]
In the citing paper
“Lp(a) is an independent risk factor for CAD and stroke.”
From Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017 (2018) · cites this paper as [222]
In the citing paper
“High Lp(a) concentrations are found in patients with FH, and it is presumed that hyper-Lp (a)-lipoproteinemia further increases the risk for CVD in patients with FH222).”
From Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017 (2018) · cites this paper as [222]
Citations
Cites
General Cardiovascular Risk Profile for Use in Primary Care: The Framingham Heart Study
D’Agostino, R. B., Vasan, R. S., Pencina, M. J., Wolf, P. A., Cobain, M., Massaro, J. M., & Kannel, W. B. (2008) · Circulation · doi:10.1161/circulationaha.107.699579 · Cited by 7,491
Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
The AIM-HIGH Investigators (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107579 · Cited by 2,911
cDNA sequence of human apolipoprotein(a) is homologous to plasminogen
McLean, J. W., Tomlinson, J. E., Kuang, W.-J., Eaton, D. L., Chen, E. Y., Fless, G. M., Scanu, A. M., & Lawn, R. M. (1987) · Nature · doi:10.1038/330132a0 · Cited by 1,886 · cited 1×
“The range of genomic variation at LPA includes copy number variation (CNV), specifically a highly polymorphic region that results from variable numbers of tandemly repeated exon sequences that encode kringle IV type 2 (KIV-2) of apo(a) [8], a pentanucleotide repeat in the LPA promoter that affects gene expression [9],…”
BackgroundRidker, P. M., Buring, J. E., Rifai, N., & Cook, N. R. (2007) · JAMA · doi:10.1001/jama.297.6.611 · Cited by 1,814
(2009) · JAMA · doi:10.1001/jama.2009.1063 · Cited by 1,753
Genetic Variants Associated with Lp(a) Lipoprotein Level and Coronary Disease
Clarke, R., Peden, J. F., Hopewell, J. C., Kyriakou, T., Goel, A., Heath, S. C., Parish, S., Barlera, S., Franzosi, M. G., Rust, S., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0902604 · Cited by 1,671 · cited 2×
“[12] described particularly strong and independent associations between CHD and two LPA variants, namely rs10455872, which is a noncoding intronic SNP, and rs3798220, which is a missense variant encoding an amino acid substitution (Ile4399Met) in the apo(a) protease-like domain.”
BackgroundBoerwinkle, E., Leffert, C. C., Lin, J., Lackner, C., Chiesa, G., & Hobbs, H. H. (1992) · Journal of Clinical Investigation · doi:10.1172/jci115855 · Cited by 962
Raal, F. J., Santos, R. D., Blom, D. J., Marais, A. D., Charng, M.-J., Cromwell, W. C., Lachmann, R. H., Gaudet, D., Tan, J. L., Chasan-Taber, S., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60284-x · Cited by 924
Ridker, P. M., Paynter, N. P., Rifai, N., Gaziano, J. M., & Cook, N. R. (2008) · Circulation · doi:10.1161/circulationaha.108.814251 · Cited by 841
Genest, J., McPherson, R., Frohlich, J., Anderson, T., Campbell, N., Carpentier, A., Couture, P., Dufour, R., Fodor, G., Francis, G. A., et al. (2009) · Canadian Journal of Cardiology · doi:10.1016/s0828-282x(09)70715-9 · Cited by 768
Self-citationSafety of anacetrapib in patients with or at high risk for coronary heart disease
Cannon, C. P., Shah, S., Dansky, H. M., Davidson, M., Brinton, E. A., Gotto, A. M., Stepanavage, M., Liu, S. X., Gibbons, P., Ashraf, T. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1009744 · Cited by 749
Seimon, T. A., Nadolski, M. J., Liao, X., Magallon, J., Nguyen, M., Feric, N. T., Koschinsky, M. L., Harkewicz, R., Witztum, J. L., Tsimikas, S., et al. (2010) · Cell Metabolism · doi:10.1016/j.cmet.2010.09.010 · Cited by 457
Self-citationBergmark, C., Dewan, A., Orsoni, A., Merki, E., Miller, E. R., Shin, M.-J., Binder, C. J., Hörkkö, S., Krauss, R. M., Chapman, M. J., et al. (2008) · Journal of Lipid Research · doi:10.1194/jlr.m800174-jlr200 · Cited by 407
Lackner, C., Boerwinkle, E., Leffert, C. C., Rahmig, T., & Hobbs, H. H. (1991) · Journal of Clinical Investigation · doi:10.1172/jci115248 · Cited by 406
Use of the Thyroid Hormone Analogue Eprotirome in Statin-Treated Dyslipidemia
Ladenson, P. W., Kristensen, J. D., Ridgway, E. C., Olsson, A. G., Carlsson, B., Klein, I., Baxter, J. D., & Angelin, B. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0905633 · Cited by 338
Apolipoprotein(a) Isoforms and the Risk of Vascular Disease
Erqou, S., Thompson, A., Di Angelantonio, E., Saleheen, D., Kaptoge, S., Marcovina, S., & Danesh, J. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.10.080 · Cited by 332
Virani, S. S., Brautbar, A., Davis, B. C., Nambi, V., Hoogeveen, R. C., Sharrett, A. R., Coresh, J., Mosley, T. H., Morrisett, J. D., Catellier, D. J., et al. (2012) · Circulation · doi:10.1161/circulationaha.111.045120 · Cited by 324
F. T. G. O. C. I., Jaeger, B. R., Richter, Y., Nagel, D., Heigl, F., Vogt, A., Roeseler, E., Parhofer, K., Ramlow, W., Koch, M., et al. (2009) · Nature Reviews Cardiology · doi:10.1038/ncpcardio1456 · Cited by 294
Efficacy and safety of an extended-release niacin (Niaspan): a long-term study
Capuzzi, D. M., Guyton, J. R., Morgan, J. M., Goldberg, A. C., Kreisberg, R. A., Brusco, O. A., & Brody, J. (1998) · The American Journal of Cardiology · doi:10.1016/s0002-9149(98)00731-0 · Cited by 254
Differences in Lp[a] concentrations and apo[a] polymorphs between black and white Americans
Marcovina, S. M., Albers, J. J., Wijsman, E., Zhang, Z., Chapman, N. H., & Kennedy, H. (1996) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)37461-7 · Cited by 237
Chasman, D. I., Shiffman, D., Zee, R. Y. L., Louie, J. Z., Luke, M. M., Rowland, C. M., Catanese, J. J., Buring, J. E., Devlin, J. J., & Ridker, P. M. (2009) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2008.07.019 · Cited by 228
Schultz, O., Oberhauser, F., Saech, J., Rubbert-Roth, A., Hahn, M., Krone, W., & Laudes, M. (2010) · PLoS ONE · doi:10.1371/journal.pone.0014328 · Cited by 225
Samaha, F. F., McKenney, J., Bloedon, L. T., Sasiela, W. J., & Rader, D. J. (2008) · Nature Clinical Practice Cardiovascular Medicine · doi:10.1038/ncpcardio1250 · Cited by 220
Taleb, A., Witztum, J. L., & Tsimikas, S. (2011) · Biomarkers in Medicine · doi:10.2217/bmm.11.60 · Cited by 187
Oxidation-Specific Biomarkers, Lipoprotein(a), and Risk of Fatal and Nonfatal Coronary Events
Tsimikas, S., Mallat, Z., Talmud, P. J., Kastelein, J. J. P., Wareham, N. J., Sandhu, M. S., Miller, E. R., Bénessiano, J., Tedgui, A., Witztum, J. L., et al. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.04.048 · Cited by 163
Tellis, C. C., & Tselepis, A. D. (2009) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2009.02.015 · Cited by 158
Tsimikas, S., Tsironis, L. D., & Tselepis, A. D. (2007) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000280571.28102.d4 · Cited by 152
Koschinsky, M. L., & Marcovina, S. M. (2004) · Current Opinion in Lipidology · doi:10.1097/00041433-200404000-00009 · Cited by 149
Self-citationEdelstein, C., Pfaffinger, D., Hinman, J., Miller, E., Lipkind, G., Tsimikas, S., Bergmark, C., Getz, G. S., Witztum, J. L., & Scanu, A. M. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m310425200 · Cited by 137
Lanktree, M. B., Anand, S. S., Yusuf, S., & Hegele, R. A. (2010) · Circulation: Cardiovascular Genetics · doi:10.1161/circgenetics.109.907642 · Cited by 135
Self-citationMoliterno, D. J., Jokinen, E. V., Miserez, A. R., Lange, R. A., Willard, J. E., Boerwinkle, E., Hillis, L. D., & Hobbs, H. H. (1995) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.15.7.850 · Cited by 126
Merki, E., Graham, M., Taleb, A., Leibundgut, G., Yang, X., Miller, E. R., Fu, W., Mullick, A. E., Lee, R., Willeit, P., et al. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.10.052 · Cited by 124 · cited 1×
“[43] recently studied an antisense oligonucleotide (ASO) targeting apo(a) mRNA in mice overexpressing apo(a) isoforms; this was the first study to directly inhibit apo(a) and Lp(a) expression in vivo.”
BackgroundAkaike, M., Azuma, H., Kagawa, A., Matsumoto, K., Hayashi, I., Tamura, K., Nishiuchi, T., Iuchi, T., Takamori, N., Aihara, K.-I., et al. (2002) · Clinical Chemistry · doi:10.1093/clinchem/48.9.1454 · Cited by 118
Lipoprotein(a) and ischemic heart disease—A causal association? A review
Kamstrup, P. R. (2010) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2009.12.036 · Cited by 117
Ramharack, R., Barkalow, D., & Spahr, M. A. (1998) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.18.6.984 · Cited by 103
Molecular basis of congenital lp(a) deficiency: a frequent apo(a) 'null' mutation in caucasians
Ogorelkova, M. (1999) · Human Molecular Genetics · doi:10.1093/hmg/8.11.2087 · Cited by 84
Genetic Variants in the Apolipoprotein(a) Gene and Coronary Heart Disease
Li, Y., Luke, M. M., Shiffman, D., & Devlin, J. J. (2011) · Circulation Cardiovascular Genetics · doi:10.1161/circgenetics.111.959601 · Cited by 70
Kagawa, A., Azuma, H., Akaike, M., Kanagawa, Y., & Matsumoto, T. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.48.34111 · Cited by 65
Cobbaert, C. M., Jukema, J. W., Zwinderman, A. H., Withagen, A. J. A. M., Lindemans, J. W., & Bruschke, A. V. G. (1997) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(97)00353-7 · Cited by 64
Chretien, J.-P., Coresh, J., Berthier-Schaad, Y., Kao, W. H. L., Fink, N. E., Klag, M. J., Marcovina, S. M., Giaculli, F., & Smith, M. W. (2006) · Journal of Medical Genetics · doi:10.1136/jmg.2006.042119 · Cited by 61
Geethanjali, F. S., Luthra, K., Lingenhel, A., Kanagasabapathy, A. S., Jacob, J., Srivastava, L. M., Vasisht, S., Kraft, H.-G., & Utermann, G. (2003) · Atherosclerosis · doi:10.1016/s0021-9150(03)00143-6 · Cited by 57
Ronald, J., Rajagopalan, R., Cerrato, F., Nord, A. S., Hatsukami, T., Kohler, T., Marcovina, S., Heagerty, P., & Jarvik, G. P. (2011) · Stroke · doi:10.1161/strokeaha.110.591230 · Cited by 47
Berthold, H. K., Laudes, M., Krone, W., & Gouni‐Berthold, I. (2011) · PLoS ONE · doi:10.1371/journal.pone.0024719 · Cited by 44
Arai, K., Luke, M. M., Koschinsky, M. L., Miller, E. R., Pullinger, C. R., Witztum, J. L., Kane, J. P., & Tsimikas, S. (2009) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2009.09.077 · Cited by 44
Self-citationPentanucleotide Repeat Polymorphism, Lipoprotein(a) Levels, and Risk of Ischemic Heart Disease
Kamstrup, P. R., Tybjærg-Hansen, A., Steffensen, R., & Nordestgaard, B. G. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0830 · Cited by 24
Cox, L. A., Jett, C., & Hixson, J. E. (1998) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)32512-8 · Cited by 20
Lipoprotein(a) accelerates atherosclerosis in uremic mice
Pedersen, T. X., McCormick, S. P. A., Tsimikas, S., Bro, S., & Nielsen, L. B. (2010) · Journal of Lipid Research · doi:10.1194/jlr.m006742 · Cited by 19
Yang, M., Chu, E. M., CASLAKE, M. J., Edelstein, C., Scanu, A. M., & Hill, J. S. (2009) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2009.10.011 · Cited by 10
Research works printed but not linked: 1
- Gudnason, 2009, Lipoprotein(a): a causal independent risk factor for coronary heart disease Curr Opin C, ardiol, 24, 490
Cited by
Lindman, B. R., Clavel, M.-A., Mathieu, P., Iung, B., Lancellotti, P., Otto, C. M., & Pibarot, P. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.6 · Cited by 982
The impact of oxidative stress and inflammation on RPE degeneration in non-neovascular AMD
Datta, S., Cano, M., Ebrahimi, K., Wang, L., & Handa, J. T. (2017) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2017.03.002 · Cited by 802
Kinoshita, M., Yokote, K., Arai, H., Iida, M., Ishigaki, Y., Ishibashi, S., Umemoto, S., Egusa, G., Ohmura, H., Okamura, T., et al. (2018) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.gl2017 · Cited by 813
Kettunen, J., Demirkan, A., Würtz, P., Draisma, H. H. M., Haller, T., Rawal, R., Vaarhorst, A., Kangas, A. J., Lyytikäinen, L.-P., Pirinen, M., et al. (2016) · Nature Communications · doi:10.1038/ncomms11122 · Cited by 738
van der Valk, F. M., Bekkering, S., Kroon, J., Yeang, C., Van den Bossche, J., van Buul, J. D., Ravandi, A., Nederveen, A. J., Verberne, H. J., Scipione, C., et al. (2016) · Circulation · doi:10.1161/circulationaha.116.020838 · Cited by 674
Self-citation
Metadata
- Authors
- Dubé, J. B., Boffa, M. B., Hegele, R. A., & Koschinsky, M. L.
- Affiliations
- Western University (CA)
- University of Windsor (CA)
- Corresponding author
- Dubé, Joseph B.
- Boffa, Michael B.
- Venue
- Current Opinion in Lipidology
- Published
- 2012-04
- Volume
- 23
- Issue
- 2
- Pages
- 133-140
- ISSN
- 0957-9672 (ISSN-L)
- OpenAlex
- W2036075350
- Cited by
- 105
- References
- 48
- Citations by year
- 2025: 1 · 2024: 1 · 2023: 3 · 2022: 1 · 2021: 1 · 2020: 3 · 2019: 11 · 2018: 8 · 2017: 10 · 2016: 20 · 2015: 8 · 2014: 12 · 2013: 15 · 2012: 11
- FWCI
- 2.84
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Current Opinion in Lipidology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Canadian Institutes of Health Research (79853_1, 79523_1, MOP13430)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- lipoprotein(a), cardiovascular risk, coronary artery disease, inflammation, atherogenesis, thrombosis, antisense oligonucleotides, apolipoprotein(a), pleiotropy, Lp(a) metabolism
- MeSH terms
- Animals, Cardiovascular Diseases, Coronary Disease, Humans, Polymorphism, Genetic, Risk Factors, Lipoprotein(a), Genetic Predisposition to Disease, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.